EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2026

NEW YORK, Dec. 26, 2017 /PRNewswire/ -- EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2026

Summary


Read the full report: https://www.reportlinker.com/p05257630


Chronic kidney disease (CKD), or chronic renal disease, is an asymptomatic, long-term condition that damages the kidneys and leads to the loss of kidney function over time (NIH, 2010). As the disease progresses, the symptoms worsen, eventually leading to kidney failure (NIH, 2010). The glomerular filtration rate (GFR), a key measure of kidney function, is determined by the amount of creatinine in the blood, and the Kidney Disease, Improving Global Outcomes (KDIGO) classification system is considered the standard for GFR measurement and diagnosis of CKD.

CKD affects people of all ages, but the risk is higher in those ages 65 years and older. Globally, the estimated prevalence of CKD is around 7% in people over the age of 30 years (Zhang and Rothenbacher, 2008). In addition, CKD is more common in women thanmen, and is also more common in people of African and South Asian origin due to the high prevalence of diabetes in South Asians and hypertension in people of African origin.

In the 7MM, our epidemiologists forecast the diagnosed prevalent cases of CKD, Stages I-V, to increase from around 25.7 million cases in 2016 to over 28.3 million cases in 2026, at an Annual Growth Rate (AGR) of almost 1%. The UK will have the highest number of diagnosed cases of CKD throughout the forecast period.

The report "EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and the global and historical trends of CKD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It also includes a 10-year epidemiological forecast for the total prevalent cases of CKD, Stages I-IV, segmented by age (beginning at 20 years and ending at ages 80 years and older), by sex, and by stage. Furthermore, this report includes a forecast of the diagnosed prevalent cases of CKD, Stages I-V, and the diagnosed prevalent cases of CKD by stage.

Scope
- The Chronic Kidney Disease EpiCast Report provides an overview of the risk factors and global trends of chronic kidney disease in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report also includes a 10-year epidemiological forecast for the total prevalent cases of CKD, Stages I-IV, segmented by age (beginning at 20 years and ending at ages 80 years and older), by sex, and by stage. Furthermore, this report includes a forecast of the diagnosed prevalent cases of CKD, Stages I-V, and the diagnosed prevalent cases of CKD by stage.
- The chronic kidney disease epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy
The Chronic Kidney Disease EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global chronic kidney disease treatment market.
- Quantify patient populations in the chronic kidney disease market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for chronic kidney disease therapeutics in each of the markets covered.
- Understand magnitude of chronic kidney disease.

Read the full report: https://www.reportlinker.com/p05257630

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/epicast-report-chronic-kidney-disease---epidemiology-forecast-to-2026-300575347.html

SOURCE Reportlinker